Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CP-751,871 + paclitaxel + carboplatin + erlotinib
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy composed of **CP-751,871 (figitumumab), paclitaxel, carboplatin, and erlotinib** evaluated primarily in the treatment of advanced or metastatic non-small-cell lung cancer (NSCLC). - **CP-751,871 (figitumumab)** is a fully human monoclonal antibody that specifically inhibits the insulin-like growth factor type 1 receptor (**IGF-1R**), a pathway implicated in tumor cell growth and survival[1][6]. - **Paclitaxel** and **carboplatin** are standard chemotherapeutic agents: paclitaxel disrupts microtubule function, and carboplatin causes DNA crosslinking, leading to apoptosis. - **Erlotinib** is a small molecule inhibitor targeting **epidermal growth factor receptor—tyrosine kinase (EGFR TK)**. This combination was investigated for potential additive or synergistic anti-tumor activity, especially for patients with advanced, treatment-naïve NSCLC. The regimen’s safety, efficacy, and tolerability have been assessed in multiple clinical studies[1][2][5].
- Brand names
- figitumumab
- Other names
- CP-751871 + paclitaxel + carboplatin + erlotinib
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)DNATUBB (Tubulin (alpha and beta subunits))IGF-1R (Insulin-like growth factor 1 receptor)
Beyond the preview
Go deeper on CP-751,871 + paclitaxel + carboplatin + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CP-751,871 + paclitaxel + carboplatin + erlotinib.